SPACs aren’t dead.
At least not to the folks at Cormorant Asset Management. Last week, the life sciences and biopharma specialist filed plans to raise $100 million for Helix Acquisition II, its second special purpose acquisition company.
“All companies coming public will go up or down according to how good their fundamentals are and develop,” Cormorant founder Bihua Chen told Institutional Investor in a text exchange.
